Substance / Medication

Dasabuvir

SNOMED 714104000 UMLS C3852512

Overview

Active Ingredient

dasabuvir

RxNorm CUI

1597381

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Viral hepatitis C

Chronic type C viral hepatitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

102 trials linked to this intervention

102

Total Trials

Recruiting

With Results

Recent Trials

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

NCT00001854Phase 4Completed50 enrolled

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

NCT00028093Phase 4Completed50 enrolled

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636Phase 4Completed1469 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

NCT00077649Phase 4Completed188 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568Phase 4Completed57 enrolled

View all 102 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.

Wedemeyer H, Craxí A, Zuckerman E et al. · J Viral Hepat · 2017

PMID: 28480525Meta-Analysis

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.

Ahmed Hussien, Abushouk Abdelrahman Ibrahim, Menshawy Amr et al. · Clin Drug Investig · 2017

PMID: 28871475Meta-Analysis

Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.

Polepally Akshanth R, Badri Prajakta S, Eckert Doerthe et al. · Eur J Drug Metab Pharmacokinet · 2017

PMID: 27165046Meta-Analysis

Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.

Saab Sammy, Mehta Darshan, Hudgens Stacie et al. · Liver Int · 2018

PMID: 29314597RCT

[Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data].

Wei L, Cheng J, Luo J et al. · Zhonghua Gan Zang Bing Za Zhi · 2018

PMID: 29996204RCT

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.

Wyles David, Saag Michael, Viani Rolando M et al. · J Infect Dis · 2017

PMID: 28329334RCT

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.

Bacinschi Xenia, Popescu Gabriel Cristian, Zgura Anca et al. · Med Sci Monit · 2022

PMID: 35787600ObservationalFull text (PMC)

Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.

Değertekin Bülent, Demir Mehmet, Akarca Ulus S et al. · Turk J Gastroenterol · 2020

PMID: 33626001ObservationalFull text (PMC)

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel.

Itkonen Matti K, Tornio Aleksi, Lapatto-Reiniluoto Outi et al. · Clin Pharmacol Ther · 2019

PMID: 29696643ObservationalFull text (PMC)

Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.

Örmeci Necati, Sezgin Orhan, Karaali Ridvan et al. · Eur J Gastroenterol Hepatol · 2019

PMID: 30672829Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Dasabuvir (substance)
SNOMED CT: 714104000
UMLS CUI: C3852512
RxNorm CUI: 1597381

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

102

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.